New drug combo shows promise for rare, aggressive prostate cancer
Disease control
Ongoing
This study tests a combination of two drugs, pembrolizumab and lenvatinib, in people with advanced neuroendocrine prostate cancer that has spread. The goal is to see if the treatment can slow tumor growth. About 45 participants will receive the drugs in 21-day cycles for up to 35…
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated May 05, 2026 11:56 UTC